ERBB2 and breast cancer: We have shown that salivary catalase activity decreases more significantly in luminal breast cancer subtypes (Lum A, Lum B(−) and Lum B(+)), while AOA decreases to a greater extent in HER2-positive (Lum B(+) and Non-Lum) and TNBC.